Associated Press, Author at 91av Science news and science articles from 91av Mon, 17 Feb 2020 16:29:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.1 242057827 Inquiry launched into 450,000 missed breast cancer screenings /article/2167926-inquiry-launched-into-450000-missed-breast-cancer-screenings/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Wed, 02 May 2018 14:13:57 +0000 /?post_type=article&p=2167926 Missed diagnosis
Missed diagnosis
Rui Vieira/PA Wire

A breast cancer screening error affecting 450,000 women may have led to hundreds of lives being cut short, health secretary Jeremy Hunt has revealed.

Hunt said that a computer algorithm failure dating back to 2009 had meant that many women aged 68 to 71 were not invited to their final routine screening.

It is not known whether any delay in diagnosis resulted in avoidable death, but it is estimated that between 135 and 270 women had their lives shortened as a result, he said.

The issue was first brought to the attention of the Department of Health and Social Care in January, but was initially thought to pose a “limited” risk to patients. It was escalated to ministers in March by (PHE), with the Government told the error should not be made public to ensure existing screening services were not overwhelmed.

“Earlier this year PHE analysis of trial data from the service found that there was a computer algorithm failure dating back to 2009,” said Hunt. “The latest estimates I have received from PHE is that as a result of this, between 2009 and the start of 2018, an estimated 450,000 women were not invited to their final breast screening. At this stage it is not clear whether any delay in diagnosis resulted in any avoidable harm or death and that is one of the reasons I am ordering an independent review to establish the clinical impact.”

“On behalf of the Government, Public Health England and the NHS, I apologise wholeheartedly and unreservedly for the suffering caused,” he added.

Screening issues

“We are deeply saddened and extremely concerned to hear that so many women have been let down by such a colossal systematic failure,” says Delyth Morgan, chief executive of charity Breast Cancer Now. “That hundreds of thousands of women have not received the screening invitations they’ve been relying upon, at a time when they may be most at risk of breast cancer, is totally unacceptable.

“We know this will unfortunately be incredibly difficult news for many women to hear. PHE will be directly contacting all women affected – we’d urge against panic and encourage anyone concerned that they have missed their screening invitations to contact the PHE helpline directly for further advice.”

Women in the UK between the ages of 50 and 70 are automatically invited for breast cancer screening every three years. The government is currently investigating the pros and cons of screening a wider age group of women between 47 and 73.

This is controversial: although breast screening sounds like a no-brainer, a growing body of research suggests that screening may do more harm than good. The main concerns are false positives and overdiagnosis – detecting and treating small cancers that, if left alone, might in fact regress or grow so slowly as to do no harm.

Read more: Critics say wider breast screening trial ‘unethical’

]]>
2167926
Stem cell therapy reverses sight loss and lets people read again /article/2164134-stem-cell-therapy-reverses-sight-loss-and-lets-people-read-again/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Mon, 19 Mar 2018 16:00:26 +0000 /?post_type=article&p=2164134 Two people with severe sight loss can now see well enough to read after receiving tissue grown from human embryonic stem cells. A man in his 80s and a woman in her 60s received the treatment for age-related macular degeneration (AMD), a condition which leads to a rapid loss of central vision. The two people went from not being able to read at all, to reading 60 to 80 words per minute with normal reading glasses. They were monitored for 12 months after the procedure and reported no severe side effects. The results are a positive step in creating a treatment for AMD, which affects more than 600,000 people in the UK. “The results suggest that this new therapeutic approach is safe and provides good visual outcomes,” says Lyndon da Cruz, consultant ophthalmologist at Moorfields Eye Hospital NHS Foundation Trust. “The patients who received the treatment had very severe AMD, and their improved vision will go some way to enhance their quality of life.”

New layers

A layer of cells called the retinal pigment epithelium (RPE) is essential for supporting and nourishing the retina cells that capture light for vision. In wet AMD, fluid leakage damages the RPE, leading to the death of light-sensitive cells and loss of vision. Da Cruz and his team grew replacement RPE cells from human embryonic stem cells on a thin plastic scaffold, before transplanting the tissue into the back of each volunteer’s eye. The new RPE cells replenished the health of the light-sensitive cells, improving vision. A similar trial of RPE cells created from induced pluripotent stem cells (iPSC) – adult cells that are transformed into stem cells – also showed some success last year. A woman with AMD had her skin cells coaxed into RPE cells. These cells were implanted next to her retina. The treatment did not improve the sharpness of her vision, but prevented further deterioration. Treatments using iPSC’s are preferable to those that use embryonic stem cells as they do not involve the destruction of human embryos. However, there has been some concern that turning adult cells into stem cells could lead to cancer-causing genetic mutations. Further trials of both techniques are needed. “This [new] study represents real progress in regenerative medicine and opens the door on new treatment options for people with age-related macular degeneration,” says Pete Coffey at the UCL Institute of Ophthalmology, part of the team who carried out the trial. “We hope this will lead to an affordable ‘off-the-shelf’ therapy that could be made available to NHS patients within the next five years.”

Nature Biotechnology

]]>
2164134